Physicians' Academy for Cardiovascular Education

SGLT2i

Looking beyond diabetes: The role of SGLT2i and MRAs in cardiorenal disease

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD

Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD

3' education - Nov. 7, 2022 - David Preiss, PhD

SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia

10' education - Oct. 24, 2022 - Prof. Silvio Inzucchi, MD

The spectrum of therapeutic options: which therapies to consider?

10' education - Oct. 18, 2022 - Prof. Ulf Landmesser, MD

SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

SGLT2i improves outcomes in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Totality of evidence of SGLT2 inhibition in HF

3' education - Aug. 27, 2022 - Muthiah Vaduganathan, MD

All patients with HF regardless of EF benefit from SGLT2i

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

10' education - July 21, 2022

Expanding evidence on SGLT2i: Where are we now and what can we expect?

10' education - July 21, 2022 - Prof. Scott Solomon, MD

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD

Management of high risk patients with HFrEF

10' education - June 28, 2022 - Prof. Javed Butler, MD and Shelley Zieroth, MD

The clinical challenges of initiating guideline recommended therapy in HF

10' education - June 21, 2022 - Prof. John McMurray, MD

Ciculating ketonse bodies in acute HF treated with SGLT2i

5' education - June 14, 2022 - Suzanne Voorrips, MD

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

Early and sustained clinical benefits with SGLT2i in HFmrEF/HFpEF

Literature - Jan. 23, 2023 - Vaduganathan M et al. - JAMA Cardiol. 2022

A prespecified analysis of the DELIVER trial showed early (<2 weeks) and sustained (>2 years) reductions in CV death or worsening HF with dapagliflozin compared with placebo in patients with HFmrEF or HFpEF.

Similar effect of SGLT2 inhibitor in HFmrEF and HFpEF

Literature - Jan. 9, 2023 - Anker SD et al. - Nat Med. 2022

The EMPEROR-Preserved trial showed that empagliflozin reduced the risk of CV death or HF hospitalization in patients with HF and LVEF >40%. However, it is unknown whether the effect of empagliflozin differs between patients with HFmrEF and those with HFpEF. This subgroup analysis of the EMPEROR-Preserved trial offers more clarity.

Background MRA or ARNI does not alter efficacy and safety of SGLT2i in HFmrEF/HFpEF

Literature - Dec. 6, 2022 - Yang M, et al. - Eur J Heart Fail. 2022

In patients with HFmrEF or HFpEF, the efficacy and safety of dapagliflozin were not influenced by background treatment with an MRA or ARNI, as shown by a prespecified analysis of the DELIVER trial.

SGLT2 inhibition leads to early decongestion and clinical benefit in acute HF

Literature - Nov. 22, 2022 - Biegus J, et al. - Eur Heart J. 2022

In 530 patients hospitalized for acute HF, empagliflozin treatment resulted in early, clinically meaningful decongestion compared with placebo. The magnitude of decongestion was associated with clinical benefit at day 90.

Looking beyond diabetes: The role of SGLT2i and MRAs in cardiorenal disease

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD
Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.

Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.

Reduced worsening of kidney disease or CV death by SGLT2i in CKD patients

News - Nov. 7, 2022

AHA 2022 In the EMPA-KIDNEY trial, use of empagliflozin reduced the outcome of worsening of kidney disease or CV death compared with placebo in CKD patients. In addition, results of a meta-analysis of 13 SGLT2i trials in high-risk patients were presented.

Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD

3' education - Nov. 7, 2022 - David Preiss, PhD
David Preiss shares the results from the EMPA-KIDNEY trial and a collaborative meta-analysis including EMPA-KIDNEY and 12 other major SGLT2i trials.

AHA 2022 David Preiss shares the results from the EMPA-KIDNEY trial and a collaborative meta-analysis including EMPA-KIDNEY and 12 other major SGLT2i trials.

Initiation, uptitration, and discontinuation of HFrEF drugs after hospitalization for HF

Literature - Oct. 24, 2022 - Savarese G, et al. - JACC Heart Fail. 2022

The observational cohort study EVOLUTION HF showed delayed initiation of novel guideline-directed medical therapies (GDMTs) after HHF in HFrEF patients in Japan, Sweden, and the USA, compared with other GDMTs.

SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia

10' education - Oct. 24, 2022 - Prof. Silvio Inzucchi, MD
The DELIVER trial investigated the effects of dapagliflozin in patients with HF and LVEF > 40%. Prof. Inzucchi shows the primary results from DELIVER and presents an update based on glycemic subgroups in the trial.

The DELIVER trial investigated the effects of dapagliflozin in patients with HF and LVEF > 40%. Prof. Inzucchi shows the primary results from DELIVER and presents an update based on glycemic subgroups in the trial.

The spectrum of therapeutic options: which therapies to consider?

10' education - Oct. 18, 2022 - Prof. Ulf Landmesser, MD
What are the current and potential future options in the precision management of patients with atherosclerotic cardiovascular disease? Prof. Landmesser presents these options per segment.

What are the current and potential future options in the precision management of patients with atherosclerotic cardiovascular disease? Prof. Landmesser presents these options per segment.

Insights into mechanism of action of SGLT2i in chronic HF using proteomics

Literature - Oct. 10, 2022 - Zannad F, et al. - Eur Heart J. 2022

By analysis of pooled plasma samples of 1134 patients from the EMPEROR-Reduced and EMPEROR-Preserved trials using large-scale proteomics, the authors identified several biological effects of empagliflozin on the heart and kidneys.

SGLT2i therapy improves NT-proBNP after AMI

Literature - Oct. 3, 2022 - Von Lewinski D, et al. - Eur Heart J. 2022

In the EMMY trial, empagliflozin treatment started within 72 hours after PCI was associated with a greater NT-proBNP decline and improved echocardiographic parameters at 26 weeks in AMI patients, without evident safety risks.